ABL1 and leukemia: Interestingly, in response to imatinib, BCR-ABL-driven human leukemia cells significantly reduced glucose consumption and lactate secretion and increased intracellular ATP levels, indicating a switch from glycolysis to mitochondrial oxidative phosphorylation [54, 55].